Ignite Creation Date:
2025-12-25 @ 12:56 AM
Ignite Modification Date:
2026-03-02 @ 10:04 PM
Study NCT ID:
NCT00546793
Status:
COMPLETED
Last Update Posted:
2021-08-16
First Post:
2007-10-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
Sponsor:
Gilead Sciences
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
IM-T-hA20-08
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None